Clinical Trial: CD8 Minibody Repeatability Study
Study Status: Completed
Recruit Status: RECRUITING
Condition: Melanoma
Study Type: INTERVENTIONAL
Official Title: Positron Emission Tomography Repeatability Evaluation of Tissue Zirconium 89Zr Crefmirlimab Berdoxam
Brief Summary:
Zr-89 crefmirlimab berdoxam is a Zirconium-89 labelled minibody developed by ImaginAb for full body PET imaging of CD8+ cell distribution (CD8 ImmunoPET).The primary objective of this study is to assess the test-retest repeatability of CD8 immunoPET imaging in oncology patients with stable disease.
Read more